Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
Type:
Application
Filed:
December 1, 2015
Publication date:
September 21, 2017
Applicants:
Inovio Pharmaceuticals, Inc., The Trustees of the University of Pennsylvania
Inventors:
David B. Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
Abstract: Disclosed herein is a vaccine comprising an antigen and IL-23. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
June 6, 2017
Assignees:
INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
David B. Weiner, Jian Yan, Matthew Morrow, Bernadette Ferraro, David Hokey
Abstract: The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.
Type:
Grant
Filed:
July 12, 2012
Date of Patent:
September 20, 2016
Assignees:
Philadelphia Health & Education Corporation, Inovio Pharmaceuticals, Inc., The Trustees of the University of Pennsylvania
Inventors:
Michele Kutzler, Scott Baliban, David B. Weiner, Niranjan Y. Sardesai, J. Joseph Kim
Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
Type:
Grant
Filed:
November 24, 2014
Date of Patent:
July 26, 2016
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B. Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
Type:
Grant
Filed:
September 8, 2014
Date of Patent:
October 13, 2015
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B. Weiner, Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
Type:
Grant
Filed:
November 24, 2014
Date of Patent:
October 13, 2015
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B. Weiner, Krystle A. Lang-Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir S. Khan
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
Type:
Application
Filed:
December 13, 2013
Publication date:
October 8, 2015
Applicant:
Inovio Pharmaceuticals, Inc.
Inventors:
David B. Weiner, Karuppiah Muthumani, Niranjan Sardesai, Seleeke Flingai
Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.
Type:
Grant
Filed:
November 2, 2010
Date of Patent:
August 18, 2015
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B Weiner, Bernadette Ferraro, Jian Yan, Patricia A Brown, Rodney A Bowling, Douglas R Kern, Mathura P Ramanathan, Niranjan Y Sardesai, Karuppiah Muthumani
Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed.
Type:
Grant
Filed:
February 8, 2011
Date of Patent:
May 19, 2015
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B Weiner, Jean D Boyer, Michele Kutzler
Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
January 6, 2015
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y Sardesai, Mathura P Ramanathan
Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
Type:
Grant
Filed:
October 20, 2011
Date of Patent:
December 30, 2014
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B Weiner, Krystle Lang, Jian Yan, Ruxandra Draghia-Akli, Amir S Khan
Abstract: The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.
Type:
Application
Filed:
July 12, 2012
Publication date:
November 20, 2014
Applicants:
Inovio Pharmaceuticals, Inc., Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
Inventors:
Michele Kutzler, Scott Baliban, David B. Weiner, Niranjan Y. Sardesai, J. Joseph Kim
Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
Type:
Grant
Filed:
October 29, 2008
Date of Patent:
September 9, 2014
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B Weiner, Krystle A. Lang Kuhs, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
Abstract: The present invention relates to DNA vaccines that are capable of generating a protective immune response in mammals against a pox virus, and comprises at least one DNA plasmid capable of expressing a plurality of VACV MV antigens, and at least one DNA plasmid capable of expressing a plurality of VACV EV antigens. Also, the present invention relates to methods of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising: injecting into tissue of said mammal said DNA vaccine.
Type:
Grant
Filed:
May 28, 2009
Date of Patent:
September 17, 2013
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
Ruxandra Draghia-Akli, Jon Prigge, Niranjan Y. Sardesai, David B. Weiner, Lauren A. Hirao
Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.
Type:
Application
Filed:
November 17, 2009
Publication date:
October 27, 2011
Applicant:
INOVIO PHARMACEUTICALS, INC.
Inventors:
Mathura P. Ramanathan, Niranjan Y. Sardesai